Prelude Therapeutics Inc (PRLD) bonds
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/3067% above fair value
$3.45−0.07 (-1.99%)
Close on Nov 13, 2026Market cap $275.32MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Prelude Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
Individual notes, bonds and loans
Prelude Therapeutics's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.
See a number that looks wrong?